Terazosin And Metabolic Engagement in Alzheimer's Disease

Summary

The TAME-AD trial will be a randomized, double-blind, placebo-controlled Phase IIa clinical trial to evaluate the metabolic target engagement of terazosin for the treatment of Alzheimer's disease.

Timeline

Start

2027-08-01

Primary completion

2031-07-31

Completion

2032-07-31

Publications

• Background Hart A, Aldridge G, Zhang Q, Narayanan NS, Simmering JE. Association of Terazosin, Doxazosin, or Alfuzosin Use and Risk of Dementia With Lewy Bodies in Men. Neurology. 2024 Jul 23;103(2):e209570. doi: 10.1212/WNL.0000000000209570. Epub 2024 Jun 19.
• Background Zhang Q, Schultz JL, Simmering JE, Kirkpatrick BQ, Weber MA, Skuodas S, Hicks T, Pierce G, Laughlin M, George B, Bertolli AX, Larson T, Thangavel R, Oya M, Meyerholz DK, Aldridge G, Fassler J, Narayanan NS. Glycolysis-enhancing alpha1-adrenergic antagonists have therapeutic potential in Alzheimer's disease. Alzheimers Res Ther. 2026 Jul 9. doi: 10.1186/s13195-026-02135-z. Online ahead of print.

Drugs

Indications